搜尋結果
2024年6月27日 · Recommendations for Ages 19 Years or Older, United States, 2024. Print. Back to Adult Immunization Schedule home page. Vaccines in the Adult Immunization Schedule. How to use the schedule. To make vaccination recommendations, healthcare providers should: Determine recommended vaccine by age ( Table 1 – By Age)
- Overview
- Risk Factors for Severe COVID-19
- Outpatient Treatments for COVID-19
•There is strong scientific evidence that antiviral treatment of persons with mild to moderate illness who are at risk for severe COVID-19 reduces their risk of hospitalization and death.
•The antiviral drugs ritonavir-boosted nirmatrelvir (Paxlovid) and remdesivir (Veklury) are the preferred treatments for eligible adult and pediatric patients who are at high risk for progression to severe COVID-19.
Clinicians can use the links below to identify patients at risk for severe COVID-19 and who may benefit from outpatient treatment. Severe outcomes of COVID-19 are defined as hospitalization, intensive care, ventilatory support, or death. There may be other medical conditions associated with severe COVID-19 not listed here, and clinical judgment is needed to accurately assess a person’s risk.
Age is the most important risk factor for severe outcomes of COVID-19. Risk factors for severe COVID-19 include:
•Age over 50 years, with risk increasing substantially at age ≥ 65 years
•Being unvaccinated or not being up to date on COVID-19 vaccinations
•Specific medical conditions, including immunocompromising conditions
Some racial and ethnic minority groups are disproportionately affected by COVID-19 because of many factors, including limited access to vaccines and healthcare.(1-3) Healthcare providers can consider these factors when evaluating the risk for severe COVID-19 and use of therapeutics.
Oral ritonavir-boosted nirmatrelvir (Paxlovid)
In a clinical trial, ritonavir-boosted nirmatrelvir reduced the risk of hospitalization and death by 86% in unvaccinated outpatients with COVID-19 at higher risk of severe disease. Serious adverse events are uncommon with Paxlovid treatment.(4) Similar results were observed in patients with prior immunity to the virus that causes COVID-19. Among patients in the EPIC-HR trial who were antibody positive at trial enrollment, the risk of COVID-19-related hospitalization or death from any cause during 28 days of follow-up was 0.2% among those treated with ritonavir-boosted nirmatrelvir compared with 1.7% of those receiving placebo. Ritonavir-boosted nirmatrelvir is given twice daily for 5 days, starting as soon as possible and within 5 days of symptom onset, and is approved for use in adults and authorized for use in pediatric patients (12 years of age and older weighing at least 40kg). Clinicians may recommend longer or additional courses of ritonavir-boosted nirmatrelvir for immunocompromised patients who continue experiencing COVID-19 symptoms after receiving antiviral treatment. Clinicians should be aware of the eligibility criteria and the potential for drug interactions with the use of ritonavir-boosted nirmatrelvir that may preclude ritonavir-boosted nirmatrelvir use or may require temporary discontinuation of other medications.
Symptomatic Management
All patients with symptomatic COVID-19 should be offered symptom management with over-the-counter antipyretics, analgesics, or antitussives for fever, headache, myalgias, and cough.(7)
More Information
For Healthcare Providers •Clinical Decision Aid for COVID-19 Outpatient Therapeutics •Side-by-Side Overview of Outpatient Therapeutics •NIH Treatment Guidelines for Non-Hospitalized Adults •FDA List of Current COVID-19 Emergency Use Authorization Products •Outpatient COVID-19 Therapeutics Administration Guide •COVID-19 Therapeutics Locator •Clinical Considerations for Children and Adults with Confirmed COVID-19 •FDA Approval for Remdesivir •Prescribing Information for Remdesivir •Emergency Use Authorization (EUA) of COVID-19 convalescent plasma for treatment of Coronavirus Disease 2019 (COVID-19) •NIH COVID-19 Treatment Guidelines: COVID-19 Convalescent Plasma •COVID-19 Therapeutics Commercialization Transition Guide | October 20, 2023 (hhs.gov) For Patients •Coronavirus (COVID-19) Drugs •What are Oral Antivirals? •COVID-19 Test to Treat Locator •COVID-19 Test to Treat Fact Sheet
Chlamydial infection is the most frequently reported bacterial infectious disease in the United States, and prevalence is highest among persons aged ≤24 years ( 141, 784 ). Multiple sequelae can result from C. trachomatis infection among women, the most serious of which include PID, ectopic pregnancy, and infertility.
2023年9月14日 · BMI Percentile Calculator for Child and Teen. Español (Spanish) This calculator provides body mass index (BMI) and the corresponding BMI-for-age percentile based on CDC growth charts for children and teens ages 2 through 19 years.
2024年3月1日 · The new guidance brings a unified approach to addressing risks from a range of common respiratory viral illnesses, such as COVID-19, flu, and RSV, which can cause significant health impacts and strain on hospitals and health care workers.
HPV vaccine works best when given before any exposure to HPV. Most sexually active adults have already been exposed to HPV, although not necessarily all of the HPV types targeted by vaccination. At any age, having a new sex partner is a risk factor for getting a new HPV infection.
2024年5月15日 · The A1C test—also known as the hemoglobin A1C or HbA1c test—is a simple blood test. Your A1C is used to diagnose prediabetes and diabetes, and monitor your progress. Find out more about the test, and your A1C goals. What does the A1C test measure? When you check your blood sugar at home, it's a snapshot of a single point in time.
